A systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countries

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Suhrcke, Marc ^a,b   Boluarte, Till A ^c   Niessen, Louis ^a,b,d  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UKCRC Centre for Diet and Activity Research (CEDAR)   (United Kingdom)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; DEVELOPING COUNTRY; ECONOMICS; FEMALE; HEALTH CARE QUALITY; HEALTH PROMOTION; HUMAN; MALE; METHODOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; DEVELOPING COUNTRIES; FEMALE; HEALTH PROMOTION; HUMANS; MALE; PROGRAM EVALUATION;

EID: 84855227716     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-2     Document Type: Article

References (45)

1. Lopez A, Disease Control Priorities Project, Global Burden of Disease and Risk Factors Washington, DC: World Bank Publications 2006
2. Leeder S, Raymond S, Greenberg H, Liu H, Esson K, A Race Against Time: The Challenge of Cardiovascular Disease in Developing Economies New York: Trustees of Columbia University 2004
3. Emerging epidemic of cardiovascular disease in developing countries. Reddy KS, Yusuf S, Circulation 1998 97 596 601 9494031 (Pubitemid 28090690)
4. World Bank, World Development Indicators 2007 Washington, DC: World Bank Publications 2007
5. The economics of primary prevention of cardiovascular disease - a systematic review of economic evaluations. Schwappach DL, Boluarte TA, Suhrcke M, Cost Eff Resour Alloc 2007 5 5 10.1186/1478-7547-5-5 17501999 (Pubitemid 46851049)
6. Economic evaluations of non-communicable disease interventions in developing countries: a critical review of the evidence base. Mulligan JA, Walker D, Fox-Rushby J, Cost Effectiveness and Resource Allocation 2006 4 7 10.1186/1478-7547-4-7 16584546 (Pubitemid 43885291)
7. HEE-GER: a systematic review of German economic evaluations of health care published 1990-2004. Schwappach DL, Boluarte TA, BMC Health Serv Res 2007 7 7 10.1186/1472-6963-7-7 17222334 (Pubitemid 46178306)
8. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group, PLoS Med 2009 6 6 10.1371/journal.pmed.1000006
9. The measurement of observer agreement for categorical data. Landis JR, Koch GG, Biometrics 1977 33 159 174 10.2307/2529310 843571 (Pubitemid 8054849)
10. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Smith SC, Allen J, Blair SN, et al. Circulation 2006 113 2363 2372 10.1161/CIRCULATIONAHA.106. 174516 16702489 (Pubitemid 43947981)
11. Summarising economic evaluations in systematic reviews: a new approach. Nixon J, Khan KS, Kleijnen J, BMJ 2001 322 7302 1596 1598 10.1136/bmj.322.7302. 1596 11431306 (Pubitemid 32592298)
12. Scaling up interventions for chronic disease prevention: the evidence. Gaziano TA, Galea G, Reddy KS, Lancet 2007 370 1939 1946 10.1016/S0140-6736(07) 61697-3 18063028 (Pubitemid 350192634)
13. Reducing the growing burden of cardiovascular disease in the developing world. Gaziano TA, Health Aff (Millwood) 2007 26 13 24 10.1377/hlthaff.26.1.13
14. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al. Lancet 2009 373 1341 1351 19339045
15. Is there underinvestment in R&D about prevention? Dranove D, J Health Econ 1998 17 117 127 10.1016/S0167-6296(97)00015-5 10176312 (Pubitemid 28042042)
16. Cost-effectiveness analysis for priority setting. Musgrove P, Fox-Rushby J, Control Priorities in Developing Countries New York: Oxford University Press and The World Bank, Jamison D, Breman J, Measham A, Alleyne G, Claeson M, Evans D et al, 2 2006 271 286
17. Revisiting Rose: strategies for reducing coronary heart disease. Manuel DG, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A, et al. BMJ 2006 332 659 662 10.1136/bmj.332.7542.659 16543339 (Pubitemid 44365729)
18. Neal B, Yangfeng W, Li N, The Effectiveness and Costs of Population Interventions to Reduce Salt Consumption Geneva: World Health Organization 2006
19. Comparative cost-effectiveness of policy instruments for reducing the global burden of alcohol, tobacco and illicit drug use. Chisholm D, Doran C, Shibuya K, Rehm J, Drug and Alcohol Review 2006 25 553 565 10.1080/ 09595230600944487 17132573 (Pubitemid 44837645)
20. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Unal B, Critchley JA, Capewell S, Circulation 2004 109 1101 1107 10.1161/01.CIR.0000118498.35499.B2 14993137 (Pubitemid 38332613)
21. WHO framework convention on tobacco control: development of an evidence based global public health treaty. Shibuya K, Ciecierski C, Guindon E, Bettcher DW, Evans DB, Murray CJ, BMJ 2003 327 154 157 10.1136/bmj.327.7407.154 12869461 (Pubitemid 36876212)
22. Tobacco addiction. Jha P, Chaloupka F, Moore J, Gajalakshmi V, Gupta P, Peck R, et al. Disease Control Priorities in Developing Countries New York: Oxford University Press and The World Bank, Jamison D, Breman J, Measham A, Alleyne G, Claeson M, Evans D et al, 2 2006 869 886
23. Adding a medicine to the WHO model list of essential medicines. Kishore SP, Herbstman BJ, Clin Pharmacol Ther 2009 85 237 239 10.1038/clpt.2008.258 19223877
24. Modes of prevention. Tulchinsky TH, Varavikova A, The New Public Health Burlington: Academic Press 2 2008 41 43
25. Committee for Medicinal Products for Human Use (CHMP), Guidelines on the Evaluation of Medicinal Products for Cardiovascular Disease Prevention London: European Medicines Agency (EMA) 2008 Doc.Ref. EMEA/CHMP/EWP/311890/2007
26. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Revicki DA, Frank L, Pharmacoeconomics 1999 15 5 423 434 10.2165/00019053-199915050-00001 10537960 (Pubitemid 29210946)
27. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. Godwin M, Ruhland L, Casson I, MacDonald S, Delva D, Birtwhistle R, et al. BMC Med Res Methodol 2003 3 28 10.1186/1471-2288-3-28 14690550
28. Relationships among self-management, patient perceptions of care, and health economic outcomes for decision-making and clinical practice in type 2 diabetes. Cobden DS, Niessen LW, Barr CE, Rutten FF, Redekop WK, Value Health 2009
29. Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. Goldenberg N, Glueck C, Vasc Health Risk Manag 2009 5 1 369 376 19475774
30. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, et al. Eur J Clin Pharmacol 2007 63 2 197 203 10.1007/s00228-006-0239-3 17200832 (Pubitemid 46147062)
31. A systematic review of adherence to cardiovascular medications in resource-limited settings. Bowry AD, Shrank WH, Lee JL, Stedman M, Choudhry NK, J Gen Intern Med 2011 26 12 1479 1491 10.1007/s11606-011-1825-3 21858602
32. Modelling in economic evaluation: an unavoidable fact of life. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, et al. Health Econ 1997 6 217 227 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0. CO;2-W 9226140 (Pubitemid 27296586)
33. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Goeree R, Burke N, O'Reilly D, Manca A, Blackhouse G, Tarride JE, Curr Med Res Opin 2007 23 671 682 10.1185/030079906X167327 17407623 (Pubitemid 46631471)
34. Ethnic variations in the pharmacological and nonpharmacological treatment of hypertension: biopsychosocial perspective. Brownley KA, Hurwitz BE, Schneiderman N, Hum Biol 1999 71 607 639 10453104 (Pubitemid 29384620)
35. Methods to assess the costs and health effects of interventions for improving health in developing countries. Evans DB, Edejer TT, Adam T, Lim SS, BMJ 2005 331 1137 1140 10.1136/bmj.331.7525.1137 16282411
36. Predicting the effectiveness of prevention: a role for epidemiological modeling. Walls HL, Peeters A, Reid CM, Liew D, McNeil JJ, J Prim Prev 2008 29 295 305 10.1007/s10935-008-0143-y 18581234
37. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Gotzsche PC, Control Clin Trials 1989 10 31 56 10.1016/0197-2456(89)90017-2 2702836 (Pubitemid 19099522)
38. Coronary heart disease policy models: a systematic review. Unal B, Capewell S, Critchley JA, BMC Public Health 2006 6 213 10.1186/1471-2458-6-213 16919155 (Pubitemid 44362469)
39. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Value Health 2003 6 9 17 10.1046/j.1524-4733.2003.00234.x 12535234 (Pubitemid 36228345)
40. World-Bank, Toward a Healthy and Harmonious Life in China: Stemming the Rising Tide of Non-Communicable Diseases Beijing: Human Development Unit, East Asia and Pacific Region, The World Bank 2011
41. Shattuck lecture. The hypertension paradox - more uncontrolled disease despite improved therapy. Chobanian AV, N Engl J Med 2009 361 878 887 10.1056/NEJMsa0903829 19710486
42. Sodium intake and hypertension. Karppanen H, Mervaala E, Prog Cardiovasc Dis 2006 49 59 75 10.1016/j.pcad.2006.07.001 17046432 (Pubitemid 44540370)
43. WHO Statistical Information System (WHOSIS), Geneva: World Health Organization 2009 http://www.who.int/whosis/en/ accessed on 14-8-2009
44. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD, Value Health 2007 10 326 335 10.1111/j.1524-4733.2007. 00186.x 17888097 (Pubitemid 47481104)
45. Anderson J, Parker W, Steyn N, Grimsrud A, Kolbe-Alexander T, Lambert E, et al. Interventions on Diet and Physical Activity: What Works: Summary Report Geneva: World Health Organization 2009